Literature DB >> 33243547

pH-responsive hyaluronic acid-based nanoparticles for targeted curcumin delivery and enhanced cancer therapy.

Hualu Lai1, Xin Ding1, Junxian Ye1, Jie Deng1, Shengmiao Cui2.   

Abstract

Curcumin (CUR) display promising antitumor effects, however, the poor water solubility severely limited its clinical application. To overcome this problem, polymeric nanocarriers have been adopted for targeted CUR delivery and enhanced cancer therapy. In this paper, utilizing an acid-labile hydrazone linkage, hydrophobic CUR was conjugated with hydrophilic hyaluronic acid (HA) to form amphiphilic HA-ADH-CUR conjugates, which could subsequently self-assemble to form nanoparticles (HA@CUR NPs) in aqueous. The in vitro drug release experiments showed that HA@CUR NPs exhibited a pH-responsive CUR release behavior, and the release rate of CUR was 73.5 % in pH 5.0. Further, in vitro cell experiments showed HA@CUR NPs could be efficiently internalized by 4T1 and MCF-7 cancer cells through CD44 receptor mediated endocytosis and successfully release CUR in acidic lysosome environment for chemotherapy. In vivo antitumor experiments showed that, compared to free CUR, HA@CUR NPs could efficiently cumulate in tumor site via EPR effect and CD44 mediated endocytosis, achieve superior therapeutic effect for tumor growth suppression. Therefore, HA@CUR NPs were a highly promising nanocarrier for hydrophobic CUR to realize enhanced cancer therapy with good biosafety.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CD44 receptor; Curcumin; Enhanced cancer therapy; Hyaluronic acid; pH-responsive

Mesh:

Substances:

Year:  2020        PMID: 33243547     DOI: 10.1016/j.colsurfb.2020.111455

Source DB:  PubMed          Journal:  Colloids Surf B Biointerfaces        ISSN: 0927-7765            Impact factor:   5.268


  6 in total

Review 1.  CD44-Targeted Nanocarrier for Cancer Therapy.

Authors:  Prashant Kesharwani; Rahul Chadar; Afsana Sheikh; Waleed Y Rizg; Awaji Y Safhi
Journal:  Front Pharmacol       Date:  2022-03-31       Impact factor: 5.810

2.  Construction of pH-sensitive targeted micelle system co-delivery with curcumin and dasatinib and evaluation of anti-liver cancer.

Authors:  Xiangle Zeng; Yawen Zhang; Xue Xu; Zhuo Chen; Lanlan Ma; Yushuai Wang; Xuliang Guo; Jianchun Li; Xiu Wang
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

3.  Curcumin and its nano-formulations: Defining triple-negative breast cancer targets through network pharmacology, molecular docking, and experimental verification.

Authors:  Zhicheng Deng; Guanghui Chen; Yonghui Shi; Ying Lin; Jiebin Ou; Hua Zhu; Junyan Wu; Guocheng Li; Li Lv
Journal:  Front Pharmacol       Date:  2022-08-08       Impact factor: 5.988

Review 4.  Effects and Mechanisms of Curcumin for the Prevention and Management of Cancers: An Updated Review.

Authors:  Zhi-Jun Yang; Si-Yu Huang; Dan-Dan Zhou; Ruo-Gu Xiong; Cai-Ning Zhao; Ai-Ping Fang; Yun-Jian Zhang; Hua-Bin Li; Hui-Lian Zhu
Journal:  Antioxidants (Basel)       Date:  2022-07-28

Review 5.  Functional Nanoparticles for Enhanced Cancer Therapy.

Authors:  Chenchen Li; Yuqing Li; Guangzhi Li; Song Wu
Journal:  Pharmaceutics       Date:  2022-08-12       Impact factor: 6.525

Review 6.  Development of Polymer-Assisted Nanoparticles and Nanogels for Cancer Therapy: An Update.

Authors:  Bibi Noorheen Haleema Mooneerah Neerooa; Li-Ting Ooi; Kamyar Shameli; Nuraina Anisa Dahlan; Jahid M M Islam; Janarthanan Pushpamalar; Sin-Yeang Teow
Journal:  Gels       Date:  2021-05-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.